Evidence map›Paper›PMID 35759756›Full record

ArticleBlood advances2022

Improvement of hemolytic anemia with GBT1118 is renoprotective in transgenic sickle mice.

Guohui Ren, Suman Setty, Xu Zhang, Alexandru Susma, Maria Armila Ruiz, Richard D Minshall, James P Lash, Victor R Gordeuk, Santosh L Saraf

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Blood advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07175051 (Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07175051 phase2recruitingnot on this mapstarted 2026, after this paper: background citation

Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin

TypeinterventionalSponsorUniversity of Illinois at ChicagoRan2026 to 2030Enrolled20ConditionsSickle Cell Anemia (HbSS, or HbSβ-thalassemia0), AlbuminuriaArmsEmpagliflozin (oral)
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Sickle Cell Disease and CKD: An Update.American journal of nephrology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Guohui RenDivision of Hematology & Oncology, Department of Medicine.
Suman SettyDepartment of Pathology.
Xu ZhangDivision of Hematology & Oncology, Department of Medicine.
Alexandru SusmaDepartment of Pathology.
Maria Armila RuizDivision of Hematology & Oncology, Department of Medicine.
Richard D MinshallDepartments of Anesthesiology and Pharmacology, College of Medicine, and.
James P LashDivision of Nephrology, Department of Medicine, University of Illinois at Chicago, Chicago, IL.
Victor R GordeukDivision of Hematology & Oncology, Department of Medicine.ORCID 0000-0003-4725-7295
Santosh L SarafDivision of Hematology & Oncology, Department of Medicine.ORCID 0000-0002-8584-4194
University of Illinois Chicago · US

Funding

Pathways of Cell-Free Hemoglobin in Sickle Cell NephropathyR01HL153161 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI SARAF, SANTOSH · 2020 to 2024
$2.0M
NHLBI NIH HHS R01 HL153161
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Anemia, Sickle CellBenzaldehydesAnimalsMiceMice, TransgenicNiacinamideBenzaldehydesGBT1118Niacinamide

Identifiers

PMID35759756
PMCPMC9636314
OpenAlexW4283705572

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.